Process intensification: Separating fact from fiction

Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success.

May 26, 2026

India’s pharma industry is going global. But can it catch up to China?

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

By Kelly Bilodeau • May 15, 2026

Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.

By Marken, UPS Healthcare Precision Logistics • May 11, 2026

Lilly to invest extra $4.5B across Indiana manufacturing

The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.

By Nathan Owens • May 8, 2026

Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus

The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.

By Nathan Owens • April 23, 2026

Trump revives pharma tariffs with 100% charges, but leaves loopholes

"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should be low," according to one analyst.

By Jonathan Gardner • April 3, 2026

Lilly unveils $3 billion production expansion in China

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.

By Jonathan Gardner • March 11, 2026

CSL breaks ground on $1.5B Illinois immunoglobulin plant expansion

The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

By Jeffrey Kinney • March 10, 2026

Building a robust in-process testing plan for cell therapy manufacturing success

The roadmap to reliable in‑process testing for cell therapy success.

Feb. 2, 2026

The crucial role of raw material selection for success in cell therapy manufacturing

 Why raw materials make or break cell therapy manufacturing success.

Jan. 26, 2026

Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3

The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

By BioPharma Dive staff • Nov. 26, 2025

Accelerating clinical timelines with softgels: An on-demand approach that cuts weeks and costs

As launches grow more complex, softgels can help developers overcome challenges during early clinical development.

Oct. 20, 2025

The self-perform edge: Fast, reliable construction for life sciences facilities

Self-perform teams bring speed, safety and certainty to life sciences construction. 

By Mike Marston, Life Sciences Core Market Leader, DPR Construction • Oct. 20, 2025

Pioneering perspectives: 4 core principles in drug packaging

Start smart: Early packaging decisions can make or break your drug's market launch. Choose the best packaging and secure the future.

By Amy Rovi – Director, Marketing – West Pharmaceutical Services • Oct. 13, 2025

Key exemptions could limit impact of Trump’s pharmaceutical tariffs

Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.

By Jonathan Gardner • Sept. 26, 2025

Trump sets tariffs on pharmaceuticals, trucks, furniture

The new levies, ranging from 25% to 100%, will go into effect Oct. 1, the president said Thursday.

By Phil Neuffer • Sept. 25, 2025

Setting cell and gene therapies up for success with a smarter CMC strategy

Being proactive — especially when it comes to testing, process development and preparing for commercialization — can greatly decrease the risk that your CGT will receive a CRL.

Sept. 22, 2025

GSK ups US investment with $30B spending plan

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.

By Ned Pagliarulo • Sept. 17, 2025

US, EU agree to terms of framework trade pact

The countries documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, pharmaceuticals and semiconductors.

By Phil Neuffer • Aug. 21, 2025

AbbVie to build API plant in Illinois as it steps up US production

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats. 

By Kristin Jensen • Aug. 13, 2025

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

By Amy Baxter • Aug. 13, 2025

Trump threatens up to 250% tariffs on pharma imports

The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the next year and a half.

By Phil Neuffer • Aug. 5, 2025

The race to scale to 1,000 liters and beyond in gene therapy manufacturing

Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full capsids.

Aug. 4, 2025

US to install country-specific tariffs Aug. 7

An executive order President Trump signed Thursday codifies rates for over 60 trading partners, including Switzerland. A probe into pharmaceuticals that’s expected to result in sectoral tariffs remains ongoing.

By Phil Neuffer • July 31, 2025

AstraZeneca grows US presence with $50B in spending plans

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.

By Ned Pagliarulo • July 21, 2025